Recently, ADAM-10 has been studied in breast cancer, especially in the human epidermal growth factor receptor 2 (HER2)-enriched subtype, and is considered a major sheddase of the HER2 receptor ectodomain [50], which contributes to HER receptor activation and induction of anticancer drug resistance [51]. Here, ERBB2 is linked to breast cancer.